Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability) (Stock code: 1246)

COMPLETION OF MAJOR AND CONNECTED TRANSACTION INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE

References are made to (1) the circular (the "**Circular**") and the notice of the extraordinary general meeting (the "**EGM**") of Boill Healthcare Holdings Limited (the "**Company**") dated 25 August 2020 in relation to, among others, the Acquisition; and (2) the announcement of the Company dated 14 September 2020 in relation to, among others, the poll results of the EGM. Capitalised terms used in this announcement shall have the same meanings as defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that all conditions precedent in respect of the Acquisition set out under the sub-section headed "Conditions precedent" in the "Letter from the Board" of the Circular have been fulfilled and Completion (including completion of the allotment and issue of the Consideration Shares) took place on 9 October 2020. 450,600,000 Consideration Shares were issued by the Company to the Vendor pursuant to the Agreement. Upon Completion, the Target Company and its subsidiaries (including the Project Company) will become subsidiaries of the Company and accordingly, their financial results and positions will be consolidated into the consolidated financial statements of the Company.

Set out below is the shareholding structure of the Company immediately before and after completion of the allotment and issue of the Consideration Shares:

| Name of Shareholders | Immediately before completion of the allotment and issue of the Consideration Shares | | Immediately after completion of the allotment and issue of the Consideration Shares | |
|---|--|----------|---|----------|
| | No. of Shares | Approx.% | No. of Shares | Approx.% |
| Vendor (Note 1) | _ | | 450,600,000 | 33.18 |
| Liyao (Note 2) | 260,000,000 | 28.65 | 260,000,000 | 19.15 |
| Sub-total for the Vendor and parties acting in | | | | |
| concert with it | 260,000,000 | 28.65 | 710,600,000 | 52.33 |
| Public Shareholders | 647,400,000 | 71.35 | 647,400,000 | 47.67 |
| Total | 907,400,000 | 100 | 1,358,000,000 | 100 |

Notes:

(1) The Vendor is wholly-owned by Boill Holding Group, which is in turn beneficially owned as to 97.64% and 2.36% by Mr. Qiu and Ms. Huang, respectively, as at the date of this announcement. Mr. Qiu is the sole director of the Vendor.

(2) Mr. Qiu is the sole shareholder of Liyao as at the date of this announcement.

By Order of the Board Boill Healthcare Holdings Limited Dai Dong Xing Executive Director and Chairman

Hong Kong, 9 October 2020

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.